Published in final edited form as:

Exp Cell Res. 2013 May 15; 319(9): 1306–1316. doi:10.1016/j.yexcr.2013.02.003.

The role of semaphorins and their receptors in vascular development and cancer

Chenghua Gu¹ and Enrico Giraudo²

¹Department of Neurobiology, Harvard Medical School, 220 Longwood Ave, Boston, MA 02115, U.S.A.

²Institute for Cancer Research at Candiolo (IRC@C), and Department of Science and Drug Technology, University of Torino, Str. Prov. 142 Km.3,95 10060 – Candiolo, Turin, Italy

Summary

Semaphorins (Semas) are a large family of traditional axon guidance molecules. Through interactions with their receptors, Plexins and Neuropilins, Semas play critical roles in a continuously growing list of diverse biological systems. In this review, we focus on their function in regulating vascular development. In addition, over the past few years a number of findings have shown the crucial role that Semas and their receptors play in the regulation of cancer progression and tumour angiogenesis. In particular, Semas control tumour progression by directly influencing the behavior of cancer cells or, indirectly, by modulating angiogenesis and the function of other cell types in the tumor microenvironment (i.e., inflammatory cells and fibroblasts). Some Semas can activate or inhibit tumor progression and angiogenesis, while others may have the opposite effect depending on specific post-translational modifications. Here we will also discuss the diverse biological effects of Semas and their receptor complexes on cancer progression as well as their impact on the tumor microenvironment.

Semaphorins and their receptors

The Semas are a large family of secreted and membrane-bound proteins originally identified as axon guidance cues and later shown to be key regulators in many biological processes including vascular development and cancer. Based on structural similarities, the Semas are grouped into 8 classes, all of which carry a N-terminal Sema domain. Semas signal via two major receptor families, Plexins and Neuropilins (Nrps or Npns). Membrane-bound Semas bind and signal directly through Plexins whereas most of the class 3 secreted Semas (Sema3A-3G) are known to bind to a holoreceptor complex consisting of Nrps as the ligand binding subunit and Plexins as the signal transducing subunit [1-3]. The exception to this rule is Sema3E, which binds its receptor Plexin-D1 directly and independently of the Nrps [4]. There are four groups of Plexins (A, B, C, and D) that have been identified so far, and similar to Semas, all Plexins have Sema domains in their extracellular region. In addition,

© 2013 Elsevier Inc. All rights reserved.

Correspondence and requests for materials should be addressed to either C.G. or E. G. Chenghua Gu (chenghua_gu@hms.harvard.edu) Department of Neurobiology, Harvard Medical School Boston, MA 02115, U.S.A. (Phone) 617-432-6364 (Fax) 617-432-1639 or Enrico Giraudo (enrico.giraudo@ircc.it) Institute for Cancer Research at Candiolo (IRC@C), and Department of Science and Drug Technology, University of Torino, Str. Prov. 142 Km.3,95 10060 - Candiolo, Turin, Italy Phone: +39-011-9933505, fax: +39-011-9933524.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Plexins have Met-related sequences (MRS) and glycine/proline-rich motifs in the extracellular region. The intracellular domains of Plexins do not have obvious enzymatic activity, but most of them have weak sequence similarity to GTPase activating proteins (GAPs) and exhibit GAP activity towards the small GTPase R-Ras [5]. Moreover, their intracellular regions all contain two highly conserved intracellular domains known together as the SEX-plexin domain. Recent structural work has revealed that binding of each homodimer arrangement of Sema and Plexin forms a heterodimer complex that then elicits a conformational change in the complex. This structural alteration transmits signals to the intracellular domain of Plexins [6]. In contrast to Plexins, Nrps (Nrp1 and Nrp2) have a very short cytoplasmic domain with a PDZ-binding motif at the C-terminal. The extracellular domains of Nrps contain two complement-binding domains (a1 and a2), two coagulation factor V/VIII homology domains (b1 and b2), and a MAM domain (c). Importantly, besides binding to Sema3s, Nrps also bind to a structurally different family of ligands, the VEGF family, and serve as their co-receptors [7]. Although the a1 domain is only required for Sema3 binding, the b1 domain is required for both Sema3 and VEGF binding [8]. Thus, determining the precise contributions of Sema3s and Nrps is complex because Nrps also control VEGF receptor signaling.

Semaphorins in developmental angiogenesis

It was initially suggested that Sema3s compete with VEGF to bind to Nrp1 and therefore Sema3s inhibit VEGF-induced angiogenesis. Some *in vitro* data also suggest that Sema3s negatively regulate endothelial migration, for example Sema3A inhibits endothelial cell migration and survival [9, 10]. However, *in vivo* studies using knockout mice thus far show very little evidence for the role of Sema3s in developmental angiogenesis except in the case of Sema3E (see below). In the case of Sema3A, no obvious developmental vascular patterning defect were found in mice selectively lacking Sema3-Nrp1 signaling [11] or mice lacking Sema3A [12]. In addition, Sema3B⁻, Sema3F⁻, and Sema3G-null mice are also viable and fertile with no overt vascular defects. Sema3C null mice die perinatally from cardiac defect [13]. Therefore, most of the Sema3s are perhaps not required for the early stages of developmental angiogenesis, but rather play a role during vessel remodeling and pathological angiogenesis (see other sections of the review). For example, Sema3A is expressed in endothelial cells and in an autocrine manner regulates endothelial cell migration and vessel remodeling by inhibiting integrin function [14]. However, the molecular mechanisms by which Sema3A regulates integrins are not fully understood. Moreover, recent work demonstrated that genetic deletion of Sema3A in mice results in severe renal vascular patterning defects, further support the role of Sema3A in angiogenic remodeling [15]. Most Sema3s have an inhibitory function on *in vitro* endothelial cell migration assays, but whether this inhibitory effect is due to competitive Nrp binding and therefore the inhibition of VEGF signaling as was originally proposed is still unclear (see more discussion in the Nrp section).

The most obvious Sema3 member to play a key role in regulating developmental angiogenesis is Sema3E and its receptor Plexin-D1. Unlike other class 3 secreted Semas that require Nrps as an obligatory ligand-binding subunit in the Plexin/Nrp holoreceptor, Sema3E can bind and signal through Plexin-D1 independent of Nrps. As a novel ligand-receptor pair, Sema3E-Plexin-D1, plays a critical role in shaping the vascular network during development [4]. During intersomitic vessel formation, Sema3E is expressed in the caudal region of each developing somite, whereas Plexin-D1 is expressed in the intersomitic blood vessels adjacent to the somite boundary in the rostral region of each somite. Sema3E acts as a repulsive cue to restrict vessel growth and branching in the intersomitic space. As a result, both Sema3E and Plexin-D1 knockout mice exhibit severe intersomitic vessel patterning defects. Specifically, the intersomitic vessels are no longer excluded from the

normal *Sema3E*-expressing caudal region of the somite and extended ectopically throughout the somites, resulting in exuberant growth and a loss of the normal segmented pattern [4, 16]. *Plexin-D1* morphant zebrafish exhibit similar defects in intersomitic vessel patterning [17]. In addition to its function in intersomitic vessel patterning, recent work also demonstrates that *Sema3E* plays a role in the initial formation of the dorsal aorta. *Sema3E* secreted from the notochord and lateral plate mesoderm are required for the formation of avascular regions that coordinate to sculpt the mouse dorsal aorta. In *Sema3E* knockout embryos, a branched aortic plexus develops abnormally with a markedly narrowed avascular midline [18]. Therefore, the repulsive gradient generated by *Sema3E* in the mouse somite as well as the notochord and lateral plate mesoderm determines the proper patterning of *Plexin-D1*-expressing intersomitic vessels and the dorsal aorta, respectively.

The molecular mechanism underlying *Sema3E*-*Plexin-D1* signaling in vascular patterning has been linked to the well known VEGF pathway by several studies in both mouse and zebrafish [19] [20] [21] [22]. In the developing retinal vasculature, *Sema3E* is expressed uniformly by retinal ganglion cells (RGCs), but *Plexin-D1* is selectively expressed in endothelial cells at the front of actively sprouting blood vessels and VEGF is necessary and sufficient for the dynamic expression of *Plexin-D1* [19] [20]. In turn, *Sema3E*-*Plexin-D1* signaling then negatively regulates VEGF-induced *Dll4*-Notch signaling and subsequently changes the tip/stalk cell ratio. As a result, a lack of *Sema3E* or *Plexin-D1* in mice leads to a disruption of vascular patterning in retinal vasculature, generating an uneven growing front and a less-branched network [19]. It has been suggested that VEGF-Notch feedback and dynamic tip and stalk cell position-shuffling promotes reiterative sprouting and branching and thus robust network formation during angiogenesis [23]. Because *Sema3E*-*Plexin-D1* signaling negatively regulates VEGF signaling, it will be interesting to know whether *Sema3E*-*Plexin-D1* is actively involved in regulating the timing of the tip/stalk cell switching during angiogenesis.

In zebrafish, the cross-talk between VEGF and *Sema3E*-*Plexin-D1* signaling are found to be mediated by soluble *Flt1* (*sFlt1*). *Plexin-D1* antagonizes VEGF signaling by promoting the expression of *sFlt1*, a *Flk1*/*VEGFR2*-decoy, in endothelial cells, and the loss of *Plexin-D1* induces the sprouting of ectopic segmental arteries [17] [21]. Therefore, the interplay between *Plexin-D1* and *VEGFR* seems to be evolutionarily conserved during vascular development. It will be interesting to determine whether *Plexin-D1* functions to regulate *VEGFR* signaling via enhancing *sFlt1* expression in mammalian vascular development. In addition, since the elimination of *Sema3E* in zebrafish does not lead to the phenotype seen in mammals [24], it will be interesting to identify the ligand(s) associate with *Plexin-D1* in fish. This result clearly demonstrates the existence of both evolutionary similarity and difference across species.

Finally, cross-talk between *Sema3E*-*Plexin-D1* and VEGF has also been shown during pathological angiogenesis, which is achieved through the activation of the small GTPase *RhoJ*. In contrast to the VEGF-induced activation of *Cdc42*, which plays a crucial role in filopodia protrusion, *Sema3E*-induced activation of *RhoJ* mediates endothelial filopodia retraction[20].

It should be mentioned that like in the nervous system, Semas can also function as an attractant in some cases. Although so far most of the data show that Semas inhibit endothelial cell migration, some Semas also exhibit pro-angiogenesis function. For example, *Sema4D*-*Plexin-B1* signaling promotes endothelial cell migration and tube formation [25, 26]. Moreover, *Sema3C* has been shown to increase endothelial migration and proliferation in renal glomeruli [27].

Neuropilins in developmental angiogenesis

The role of Nrps in angiogenesis is complicated by the fact that they bind to both Sema3s and VEGF families. Large amounts of *in vitro* work trying to elucidate the precise function of Nrps in angiogenesis have generated controversial results and the interpretations of these studies make Nrps even more mysterious. For example, when Nrp1 was originally identified as a receptor for VEGF, the authors showed that in heterologous cells, Nrp1 and VEGFR2 were capable of forming a complex that could be immunoprecipitated only in the presence of VEGF-165, which binds both receptors. Therefore, they proposed that VEGF forms a bridge between the two proteins [28]. It has been shown that when stimulated with VEGF, endothelial cells only expressing Nrp1 do not migrate, endothelial cells only expressing VEGFR2 migrate, whereas those expressing both Nrp1 and VEGFR2 showed enhanced chemotaxis compared with endothelial cells expressing VEGFR2 alone [10] [29]. Nrp1/VEGFR2 complex formation has been shown to require the PDZ-binding domain of Npn-1 [30]. A recent *in vitro* loss of function study showed that when VEGF binding to Npn1 was abolished, the Nrp1/VEGFR2 association was disrupted [31]. However, it has not been shown definitively whether Nrp1 in association with VEGFR2 has a higher affinity for VEGF than VEGFR2 alone. It has also not been demonstrated whether Nrp1 increases the intrinsic catalytic activity of the VEGFR2 kinase domain. Moreover, there is disagreement in the literature as to whether the association of Nrp1 and VEGFR2 is VEGF-dependent, with some groups reporting VEGF-induced Nrp1 association with VEGFR2 [28, 32], while other studies were able to co-immunoprecipitate VEGFR2 and Nrp1 in the absence of VEGF [33] [34]. These disagreements in literature could be due to different *in vitro* settings and overexpression systems. *In vivo* loss of function experiments are required to address the precise role of Nrps in developmental angiogenesis.

Some *in vitro* studies have also proposed that VEGF binding to Nrp1 can lead to signaling through Nrp1 itself. For example, one study used a chimeric receptor consisting of the extracellular portion of the EGF receptor and the intracellular domain of Nrp1 and found that activation of this receptor with EGF was able to induce cell migration that was not present when cells were transfected with wild-type Nrp1 or wild-type EGFR [35]. Although Nrp1 has a very short intracellular domain (ICD) with little homology to known signaling domains, the very C-terminal of the ICD contains a PDZ-binding motif. A yeast two-hybrid screen was used to screen for proteins that interact with the ICD, and a protein called GIPC was identified and shown to bind to the PDZ binding motif [36]. However, GIPC knockout mice have a fairly mild vascular phenotype compared to the Nrp1 null [37]. A separate study found that VEGF-induced migration of HUVECs was reduced in cells that were infected with an adenovirus vector encoding Nrp1 lacking its C-terminus [38]. Yet, mice lacking the Nrp1 ICD domain were shown to have none of the embryonic vascular or cardiac defects of Nrp1 nulls [39].

Several mouse models have been generated that allow us to delineate Nrp1 function in angiogenesis *in vivo*. First, consistent with its dual binding to Sema3 and VEGF, Npn-1 null mice die very early during embryogenesis and exhibit both neural and vascular defects [40, 41]. Second, mice lacking Nrp1 specifically in endothelial cells demonstrated that Nrp1 is cell autonomously required for developmental angiogenesis in endothelial cells [11]. When the conditional Nrp mice were generated and crossed with an endothelial-specific Cre line (*Tie2-Cre*), the mutant embryos exhibit severe vascular defects including large and abnormal clumps of vascular aggregates. In contrast, neuronal-Cre-driven Nrp1 mutants (*Npn1^{fllox/flox}; Nestin-Cre*) have none of the vascular defects of the endothelial-Cre-driven mutants, but do recapitulate the defasciculation defects seen in the Nrp1 null. Therefore, Nrp protein is absolutely essential in endothelial cells for developmental angiogenesis. Third, to further address which ligands are responsible for Nrp1's anti-angiogenesis function in

endothelial cells, another mouse line, *Npn1^{Sema-}* mice carrying a mutation that specifically abolishes Sema3 binding but not VEGF binding were generated [11]. Like the neuronal-specific knockout, the *Npn1^{Sema-}* mice have a variety of neural developmental defects, but surprisingly, did not exhibit any vascular phenotypes. This *in vivo* result demonstrated that Sema3A-Npn1 interaction is critical for nervous system development, while also indicating that this interaction is dispensable for vascular development. Therefore, the severe vascular defects observed in mice lacking Npn-1 in endothelial cells (*Tie-2 Cre; Npn-1^{fl/fl}*) together with the absence of vascular defects in mice selectively abolishing Sema3-Npn1 binding (*Npn1^{Sema-}*) suggest that it is most likely that VEGF-Npn-1 interaction that is responsible for the critical function of Npn-1 in developmental angiogenesis. Mice carrying a mutation that specifically abolishes VEGF binding without affecting Sema3 binding (*Npn-1^{VEGF-}*) will be needed to test this hypothesis.

Although *in vitro* and *in vivo* studies over the past decades have furthered our understanding of the role of Nrp1 in angiogenesis, more questions have also been raised. So far there still remains several possible mechanisms underlying Nrp function in endothelial cells. One possibility is that the VEGF-Nrp1 interaction is critical for angiogenesis because it enhances VEGFR2 signaling. Another hypothesis raised recently is that Npn1 aids in VEGFR2 recycling following VEGF stimulation. In heterologous cells expressing only VEGFR2, VEGF stimulation leads to the internalization of VEGFR2 into Rab7-positive vesicles that are destined for degradation [42]. However, in the presence of Nrp1, VEGF stimulation leads to internalization of the Nrp1/VEGFR2 complex into Rab11-positive vesicles, which are then recycled back to the cell surface. Whether this occurs *in vivo* is still awaiting examination. Finally, since Nrp1 has a large extracellular domain, it is formally possible that a ligand other than Sema3 and VEGF mediates its function in developmental angiogenesis. For example, when Nrp was initially identified as an adhesion molecule, it was suggested that a “ligand” may exist to mediate its function. However, such ligand has not yet been identified.

Plexins in developmental angiogenesis

The function of plexins in developmental angiogenesis is relatively unknown in comparison to Semas and Nrps. First, it is unclear whether plexins are actually expressed in endothelial cells, although several studies have suggested weak endothelial cell expression of PlexinA [14]. PlexinA1-PlexinA2-, PlexinA-3 and PlexinA4-null mice are all viable and fertile with no vascular abnormalities reported. Thus far, Plexin-D1 is the best characterized plexin that shown strong and broad endothelial cell expression and *in vivo* functional requirement for developmental angiogenesis. Please see details above in the role of Sema3E section, and also another recent review [43].

Semas control tumour progression

Sema3s have a direct effect on cancer cells. The first evidence suggesting a potential role of Semas in controlling tumor angiogenesis derived from the identification of Sema3F as tumor suppressor in distinct deletion of 3p21.3 chromosomal region in lung cancer [44, 45]. Stemming from these data, several findings in recent years described Sema3s as modulators of cancer growth. For instance Sema3F inhibit cancer growth and metastasis formation in different xenograft mouse models [46]. In addition, it has been observed that the transcription repressor zinc finger E-box binding homeobox-box (ZEB)-1, highly up-regulated in lung cancer cells, inhibits the expression of Sema3F in these cells [47] and that, the up-regulation of Id2 in metastatic tumors over-expressing c-myc, inhibits Sema3F expression [48]. Other Sema3s, such as Sema3A, Sema 3B and Sema3F have anti-tumor effects. Indeed, Sema3A blocks breast cancer cell migration and invasion through an

inhibitory autocrine mechanism involving its receptor Nrp-1 that modulates tumour cell motility [49, 50]. Moreover, the over-expression of *Sema3A* halts the migration and invasion in prostate cancer cells [51] and strongly impairs cell migration, invasion and suppress tumor growth and metastasis in melanoma cells [52]. *Sema3B*, similarly to *Sema3F* was identified as potential tumor suppressor. *Sema3B* is lost in lung cancer, and in neuroblastoma [53, 54] and can act directly on lung tumor cells by inhibiting anchorage-independent growth and inducing apoptosis [53].

Several reports described that Semas other than *Sema3s* regulate tumor progression. For instance *Sema4D*, a single pass transmembrane protein, binding plexin-B1 receptor in tumor cells and by inducing the phosphorylation of Met and Ron, promotes tumor invasion and tumor metastasis [55, 56]. In addition, *Sema4D* induces tumor progression of head and neck squamous cell carcinomas [57]. Another example is *Sema6D*, a membrane-anchored semaphorin that use Plexin-A1 as its receptor. Interestingly, *Sema6D*, binding Plexin-A1 in complex with VEGFR-2, mediates survival and anchorage-independent growth of malignant mesothelioma cells [58]. Since both Plexin-A1 and VEGFR-2 are expressed on endothelial cells (ECs) it is possible that *Sema6D* could act also as a pro-angiogenic factor, but, this specific effect on the vasculature, has to be clarified.

Semas regulate tumor angiogenesis

A growing body of evidence so far implicate Semas as important modulators of both physiological and tumor angiogenesis [59-61] [62]. Several *in vitro* and *in vivo* studies demonstrate that *Sema3s* regulate angiogenesis. For instance *Sema3A* synergize with *Sema3F* to induce endothelial cell apoptosis [9] Interestingly, *Sema3A* and *Sema3F*, are expressed by ECs and may exert their effects in an autocrine fashion. Indeed, endogenous *Sema3A* controls, through autocrine loops, EC motility and vessel remodeling by inhibiting integrin function [63].

Sema3s controls tumor angiogenesis as well. In fact, it has been recently demonstrated, in different mouse models of spontaneous tumorigenesis, i.e. RIP-Tag2 neuroendocrine pancreatic tumour, K14-HPV16 skin carcinoma and HPV16/E₂ uterine cervix carcinoma that *Sema3A* is an endogenous angiogenic inhibitor that is lost during tumor progression, when abnormal angiogenesis takes place. Notably, its re-expression in RIP-Tag2 tumors by adeno-associated virus (AAV)-8 inhibits tumour growth, decreases vascular density, enhances pericyte coverage, and significantly enhances the survival of treated animals compared with controls [64]. Other studies, describing that systemic delivery of *Sema3A* in different mouse models of cancer impairs angiogenesis and metastasis formation [65], further highlights the anti-angiogenic and anti-tumor effect of *Sema3A*. Re-expression of *Sema3A* in the tumors results in vessel normalization and in reduced tumor hypoxia. These findings further corroborate several evidence describing that the poorly functional tumor vasculature is due to an imbalance between pro- and anti-angiogenic factors as result of an overproduction of pro-angiogenic factors, such as VEGF [66] and a loss of angiogenic inhibitors such as *Sema3A* (and *Sema3F*) [64]. The restoration of this equilibrium in tumors induces a more functional and normalized vasculature [67]. It is well documented that tumor vessel normalization, a process occurring in response to the anti-angiogenic therapies that renders the tumor vasculature more efficient in delivering oxygen and drugs, represent a remarkably advantageous anti-cancer strategy, being also able to favor chemotherapy delivery and response to radiotherapy [66, 68, 69]. In this context, more recent data describe that *Sema3A*, by normalizing the vasculature, overcomes the resistance to the anti-angiogenic therapies. In fact, the simultaneous administration of *Sema3A* with the tyrosine kinase (TK) inhibitor Sunitinib or with the anti-VEGFR-2 antibody DC101, by increasing the normalization window and inhibiting tumor hypoxia, efficiently halts metastasis

formation induced by these drugs in both RIP-Tag2 and HPV16/E₂ mouse models [70]. In addition, the administration of Sema3A as single agent or combined with Sunitinib in RIP-Tag2 insulinoma, by improving vessel function, enhances the amount of doxorubicin delivered to the tumors. Interestingly, Sema3A-mediated reduction of tumor hypoxia, is able to lessen several hypoxia-induced pathways [70], such as hypoxia-inducible factor (HIF)-1 α and NF- κ B transcription factor, to inhibit Met TK receptor and to halt the epithelial-mesenchymal transition (EMT), shown to be highly involved in the promotion of a pro-invasive and metastatic phenotype [71, 72]. The underlying mechanisms regulating the pro-normalizing effects of Sema3s in cancer remain unclear. For instance, it remains to be elucidated how Sema3A (or other Sema3s) modulate the recruitment of resident or bone-marrow-derived perivascular cells to tumor vessels and which receptors, such as Nrps and PlexinAs expressed in both ECs and pericytes and their signaling pathways, are involved in this process.

Another important Sema3, first described to have a potent direct anti-angiogenic activity, is Sema3F. In fact Sema3F blocks tumor angiogenesis and metastasis formation in mouse models of cancer [46, 73]. Very recently it has been shown that, similarly to Sema3A, Sema3F may act as an vascular normalizing agent. Indeed, it has been observed the down-modulation of Sema3F in Schwannomas in which the expression of the onco-suppressor merlin/ neurofibromatosis-2 is lost, releases the pro-angiogenic activity of VEGF-A, that, in turn, induces tumor vessel abnormalization [74]. Of note, re-expression of Sema3F in merlin/ neurofibromatosis-2 null cancer cells efficiently decreased tumor growth and normalizes the vasculature by reducing vessel area and permeability and by increasing pericyte vessel coverage [75]. Also Sema3E, similarly to Sema3A and Sema3F inhibits tumor angiogenesis. In fact Sema3E exert its anti-angiogenic effect through PlexinD1 in endothelial cells [76]. Differently from Sema3A and Sema3F, the furin-dependent proteolytic cleavage of Sema3E generates a 61 kDa isoform capable to enhance EC migration and promote metastatic spreading of breast cancer cells [77]. Moreover, by binding to PlexinD1, the 61 kDa Sema3E protein induces PlexinD1 association to the ErbB2 receptor and the consequent activation the ErbB2/neu oncogenic kinase in tumor cells [78]. Notably, recent studies shows that a furin non-cleavable form of Sema3E that binds to PlexinD1 but does not induce the association with ErbB2, strongly inhibits angiogenesis and hampers metastatic spreading in different mouse models of cancer [79]. Other Sema3s, besides their direct tumor properties, display anti-angiogenic effects. For instance, studies demonstrate that Sema3B is an efficient angiogenic inhibitor in experimental angiogenesis, and that this inhibitory activity is abrogated by furin-like pro-protein convertases [80]. More recently, a new role has been described for Sema3D in hampering tumor angiogenesis in glioblastoma tumor mouse model [81].

Probably, the most studied pro-angiogenic Sema is Sema4D. The soluble cleaved extracellular portion of Sema4D, promotes tumor angiogenesis by binding PlexinB1 [25, 57]. Interestingly, the binding of Sema4D to Plexin-B1, enhances Met phosphorylation inducing, in turn, tumor angiogenesis, invasion and metastasis dissemination [26]. Another potent pro-angiogenic Sema is Sema5A, a membrane-anchored Sema that, binding to PlxnB3, strongly enhance angiogenesis and metastasis formation in tumor pancreatic mouse models [82].

Semas modulate the function of tumor-associated macrophages and fibroblasts

A growing body of evidences described how tumour-associated inflammatory cells (e.g. macrophages and neutrophils) and cancer-associated fibroblasts (CAFs), represent key players in the regulation of cancer angiogenesis, invasion and metastatic dissemination [83,

84]. Studies have recently demonstrated that Semas and their receptors can regulate tumor angiogenesis and progression acting on these stroma cell types.

Sema and inflammation in cancer

Tumour angiogenesis is modulated by the recruitment of a series of bone marrow-derived cells (BMDCs) [83]. Among these cells, tumour-associated macrophages (TAMs) promote tumour angiogenesis [85] as well as the acquired resistance to anti-VEGF-A/VEGFR therapies [86]. Even though recent data demonstrate the presence in cancers of several subtypes of BMDCs with different and specific properties [83, 85], it is conceivable to generalize that the shift of TAMs from an anti-tumor M1 polarization to a M2 alternatively activated phenotype induces tumor angiogenesis and support tumor progression [87].

It is known that Semas regulate the immune system [88] and modulate the function of TAMs, contributing to the regulation of tumor angiogenesis. For instance, *Sema3B*, considered potential tumor suppressor and down-modulated in many cancers [53, 54], surprisingly, can promote metastasis formation by recruiting TAMs to the tumors. Indeed, *Sema3B* induces the production of IL-8 in cancer cells that contribute to the recruitment of TAMs that sustain tumor angiogenesis and progression [89]. Also *Sema4A*, a membrane-anchored Sema that binds to *plexinD1*, has a dual effect on angiogenesis. Indeed, it has been shown that *Sema4A* impairs physiological angiogenesis by acting directly on endothelial cells [90]. Recent studies demonstrate that *Sema4A*, binding *Plexin-D1* expressed in macrophages, exerts a pro-angiogenic effect by enhancing VEGF-A production in these cells [91]. Notably, *Sema4A* is greatly expressed in macrophages activated by inflammatory stimuli and recruited at the injured area in a cardiac ischemia/reperfusion model [91], suggesting its potential role in regulating pathological angiogenesis. Interestingly, *Sema7A*, shown to promote experimental angiogenesis [92], also enhances the production of several pro-inflammatory molecules (e.g., IL-8, IL-6 and IL-1 β) in macrophages and increases their migration [93]. *Sema4D* secreted by TAMs enhances tumor angiogenesis and contributes to the maturation of tumor blood vessels. Interestingly, a reduced recruitment to the tumors have been observed for TAMs derived from *Sema4D* knockout mice, compared with those derived from control animals [94].

Recent findings show that certain Semas or *Nrp-1* or other Sema receptors may define specific BMDC populations that can be recruited into cancers. For instance different Semas and their receptors (such as *Nrp-1*, *PlxnA1* and *Sema6D*) are specifically expressed by subsets of myeloid cells in cancers [95] and *Nrps* and *PlxnAs* are differently modulated in M2-compared to M1-polarized human macrophages [96]. It has been shown that changes in TAMs polarization can regulate tumor vessel normalization. In fact, recent data demonstrate that, in different mouse models of cancer, the histidine-rich glycoprotein (HRG) hampers cancer metastasis and normalizes the tumor vasculature by switching M2-like into M1-like phenotype. Notably, both *Sema3A* and VEGF-A are able to recruit a *Nrp-1*-expressing BMDCs that promote arterial maturation during physiological angiogenesis [97]. More recent studies shows that *Sema3A* recruits a specific subset of *Nrp-1*⁺, *Cd11b*⁺, *Gr-1*⁻, *Tie-2*⁻ monocytes (NEM) in tumors mouse models of cancer capable to block cancer growth and to normalize the vasculature [98]. In addition, this specific NEM sub-population, can be purified from BM of normal mice and retains its anti-tumor and pro-normalizing effects when injected in tumor-bearing mice [98]. Interestingly, while *Sema3A* exerts a chemoattractant effect on NEMs, it induces apoptosis in M2 human macrophages, known to express *Nrp-1* [96]. These findings indicate that Semas and, in particular, *Sema3s* may differentially regulate macrophages depending on the expression of specific *Sema3* receptors in myeloid populations present in cancers, and, consequently, regulate tumour angiogenesis.

Sema and cancer-associated fibroblasts

Cancer-associated fibroblasts (CAFs) or myofibroblasts, derived from mesenchymal stem cells, BM-derived or local fibroblasts, promote tumor angiogenesis and cancer progression [83, 84, 99]. To date there are no direct experimental evidences describing effects of Semas on CAFs, but recent data suggest that Sema3 receptors may have a role in their regulation in tumors. For instance, recent studies shows that Nrp-1 induces $\alpha 5\beta 1$ integrin-mediated fibronectin fibril assembly, involved in regulation of matrix stiffness and tumor progression [100]. In addition Nrp-1, acting as TGF- $\beta 1$ co-receptor, regulates the phosphorylation of Smad proteins and activate the fibroblasts promoting their conversion in myofibroblasts [101], described to support tumor growth and dissemination. Notably, it has been reported how leukocytes and CAFs can regulate each other and, together, contribute to cancer progression [83, 84]. In fact it has been shown that CAFs can regulate the activation of several immune cells and, by producing pro-inflammatory molecules, can recruit BMDCs able to promote tumor angiogenesis [102].

These data suggest therefore that Sema3s, their receptors and maybe other Semas may regulate the cross-talk between CAFs and inflammatory cells, and together, may contribute to the fine regulation of cancer microenvironment and tumor progression.

Concluding remarks

Work over the past decade has revealed increasingly important roles of semaphorins in vascular development and cancer, and has led to the identification of many new interactions between specific semaphorins and their receptors (Fig.1.). These unique ligand-receptor interactions regulate diverse aspects of vascular development and cancer progression, although we are still in the beginning stage of understanding these biological processes and their dynamic regulation. Many intriguing questions with respect to semaphorin signaling and function remain to be answered. For example, how are the different binding modes between semaphorins and receptor(s) (one ligand with multiple receptors or vice versa, forward or reverse signaling, trans or cis interactions) regulated? How are different ligand-receptor pairs assigned to different aspects of endothelial cell behavior, vessel sprouting and network formation? One important future challenge is to understand precisely how semaphorin ligand binding translates into plexin activation and downstream signaling event in vivo. Semas and their receptors are abnormally expressed during tumor progression both in cancer and stroma cells and their deregulated signal pathways may support or inhibit tumor growth and angiogenesis. A growing body of evidences demonstrate that these versatile roles of Semas in tumors depend on the different Plexins and Nrps complexes present in different tumor types and on their interaction with receptor tyrosine kinases and integrins. For instance, current studies shows that the cleaved 61 kDa form of Sema3E, binding PlexinD1, induces the association to the ErbB2 receptor in tumor cells, [75] and that Sema4D binding Plexin-B1, induces Met activation [26] promoting, in both cases, metastatic spreading. In addition, recent data describes that Nrp-1 forms a complex with EGFR controlling its activation in tumors [103]. These receptors complexes are differently expressed in tumor and stroma cells (*i.e.* ECs, pericytes, BMDCs and CAF) and can activate multiple signaling modules that can impair or promote cancer growth, angiogenesis, and metastasis dissemination. A better understanding of the global signaling partners and of the cross-talk between the multiple Semas signaling in the different cancer cell types will allow to better predict the outcome of the anti-angiogenic and anti-tumor therapies and to improve their efficacy.

Acknowledgments

We thank Nellwyn Hagan for helpful comments on the manuscript and Aleksandra Tata for figure illustration. The authors apologize to researchers whose work we could not cite due to space limitations. This work was supported by the following grants: Whitehall and Klingenstein foundations (to C.C.), Sloan research fellowship (to C.G.), Loreen Arbus Fellowship (to C.G.), March of Dimes Basil O'Connor award (to C.G.), Armenise junior faculty award (to C.G.), and NIH grant R01NS064583 (to C.G.). The authors acknowledge financial support from Associazione Italiana per la Ricerca sul Cancro (AIRC) (to E.G., IG #11600); AIRC 2010 Special Program in Molecular Clinical Oncology 5×1000 Project no. 9970 (E.G.); Fondazione Piemontese per la Ricerca sul Cancro, Intramural Grant Program 2010 (to E.G.).

References

- [1]. Kolodkin AL, Matthes DJ, O'Connor TP, Patel NH, Admon A, Bentley D, Goodman CS. Fasciclin IV: sequence, expression, and function during growth cone guidance in the grasshopper embryo. *Neuron*. 1992; 9:831–845. [PubMed: 1418998]
- [2]. Luo Y, Raible D, Raper JA. Collapsin: a protein in brain that induces the collapse and paralysis of neuronal growth cones. *Cell*. 1993; 75:217–227. [PubMed: 8402908]
- [3]. Pasterkamp RJ, Kolodkin AL. Semaphorin junction: making tracks toward neural connectivity. *Current opinion in neurobiology*. 2003; 13:79–89. [PubMed: 12593985]
- [4]. Gu C, Yoshida Y, Livet J, Reimert DV, Mann F, Merte J, Henderson CE, Jessell TM, Kolodkin AL, Ginty DD. Semaphorin 3E and plexin-D1 control vascular pattern independently of neuropilins. *Science*. 2005; 307:265–268. [PubMed: 15550623]
- [5]. Oinuma I, Ishikawa Y, Katoh H, Negishi M. The Semaphorin 4D receptor Plexin-B1 is a GTPase activating protein for R-Ras. *Science*. 2004; 305:862–865. [PubMed: 15297673]
- [6]. Nogi T, Yasui N, Mihara E, Matsunaga Y, Noda M, Yamashita N, Toyofuku T, Uchiyama S, Goshima Y, Kumanogoh A, Takagi J. Structural basis for semaphorin signalling through the plexin receptor. *Nature*. 2010; 467:1123–1127. [PubMed: 20881961]
- [7]. Soker S, Takashima S, Miao HQ, Neufeld G, Klagsbrun M. Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor. *Cell*. 1998; 92:735–745. [PubMed: 9529250]
- [8]. Gu C, Limberg BJ, Whitaker GB, Perman B, Leahy DJ, Rosenbaum JS, Ginty DD, Kolodkin AL. Characterization of neuropilin-1 structural features that confer binding to semaphorin 3A and vascular endothelial growth factor 165. *The Journal of biological chemistry*. 2002; 277:18069–18076. [PubMed: 11886873]
- [9]. Guttmann-Raviv N, Shraga-Heled N, Varshavsky A, Guimaraes-Sternberg C, Kessler O, Neufeld G. Semaphorin-3A and semaphorin-3F work together to repel endothelial cells and to inhibit their survival by induction of apoptosis. *J Biol Chem*. 2007; 282:26294–26305. [PubMed: 17569671]
- [10]. Miao HQ, Soker S, Feiner L, Alonso JL, Raper JA, Klagsbrun M. Neuropilin-1 mediates collapsin-1/semaphorin III inhibition of endothelial cell motility: functional competition of collapsin-1 and vascular endothelial growth factor-165. *The Journal of cell biology*. 1999; 146:233–242. [PubMed: 10402473]
- [11]. Gu C, Rodriguez ER, Reimert DV, Shu T, Fritsch B, Richards LJ, Kolodkin AL, Ginty DD. Neuropilin-1 conveys semaphorin and VEGF signaling during neural and cardiovascular development. *Developmental cell*. 2003; 5:45–57. [PubMed: 12852851]
- [12]. Vieira JM, Schwarz Q, Ruhrberg C. Selective requirements for NRP1 ligands during neurovascular patterning. *Development*. 2007; 134:1833–1843. [PubMed: 17428830]
- [13]. Feiner L, Webber AL, Brown CB, Lu MM, Jia L, Feinstein P, Mombaerts P, Epstein JA, Raper JA. Targeted disruption of semaphorin 3C leads to persistent truncus arteriosus and aortic arch interruption. *Development*. 2001; 128:3061–3070. [PubMed: 11688556]
- [14]. Serini G, Valdembri D, Zanivan S, Morterra G, Burkhardt C, Caccavari F, Zammataro L, Primo L, Tamagnone L, Logan M, Tessier-Lavigne M, Taniguchi M, Puschel AW, Bussolino F. Class 3 semaphorins control vascular morphogenesis by inhibiting integrin function. *Nature*. 2003; 424:391–397. [PubMed: 12879061]

- [15]. Reidy KJ, Villegas G, Teichman J, Veron D, Shen W, Jimenez J, Thomas D, Tufro A. Semaphorin3a regulates endothelial cell number and podocyte differentiation during glomerular development. *Development*. 2009; 136:3979–3989. [PubMed: 19906865]
- [16]. Gitler AD, Lu MM, Epstein JA. PlexinD1 and semaphorin signaling are required in endothelial cells for cardiovascular development. *Developmental cell*. 2004; 7:107–116. [PubMed: 15239958]
- [17]. Torres-Vazquez J, Gitler AD, Fraser SD, Berk JD, Van NP, Fishman MC, Childs S, Epstein JA, Weinstein BM. Semaphorin-plexin signaling guides patterning of the developing vasculature. *Developmental cell*. 2004; 7:117–123. [PubMed: 15239959]
- [18]. Meadows SM, Fletcher PJ, Moran C, Xu K, Neufeld G, Chauvet S, Mann F, Krieg PA, Cleaver O. Integration of repulsive guidance cues generates avascular zones that shape mammalian blood vessels. *Circulation research*. 2012; 110:34–46. [PubMed: 22076636]
- [19]. Kim J, Oh WJ, Gaiano N, Yoshida Y, Gu C. Semaphorin 3E-Plexin-D1 signaling regulates VEGF function in developmental angiogenesis via a feedback mechanism. *Genes & development*. 2011; 25:1399–1411. [PubMed: 21724832]
- [20]. Fukushima Y, Okada M, Kataoka H, Hirashima M, Yoshida Y, Mann F, Gomi F, Nishida K, Nishikawa S, Uemura A. Sema3E-PlexinD1 signaling selectively suppresses disoriented angiogenesis in ischemic retinopathy in mice. *The Journal of clinical investigation*. 2011; 121:1974–1985. [PubMed: 21505259]
- [21]. Zygmunt T, Gay CM, Blondelle J, Singh MK, Flaherty KM, Means PC, Herwig L, Krudewig A, Belting HG, Affolter M, Epstein JA, Torres-Vazquez J. Semaphorin-PlexinD1 signaling limits angiogenic potential via the VEGF decoy receptor sFlt1. *Developmental cell*. 2011; 21:301–314. [PubMed: 21802375]
- [22]. Tamagnone L, Mazzone M. Semaphorin signals on the road of endothelial tip cells. *Developmental cell*. 2011; 21:189–190. [PubMed: 21839915]
- [23]. Jakobsson L, Franco CA, Bentley K, Collins RT, Ponsioen B, Aspalter IM, Rosewell I, Busse M, Thurston G, Medvinsky A, Schulte-Merker S, Gerhardt H. Endothelial cells dynamically compete for the tip cell position during angiogenic sprouting. *Nature cell biology*. 2010; 12:943–953.
- [24]. Lamont RE, Lamont EJ, Childs SJ. Antagonistic interactions among Plexins regulate the timing of intersegmental vessel formation. *Developmental biology*. 2009; 331:199–209. [PubMed: 19422817]
- [25]. Basile JR, Barac A, Zhu T, Guan KL, Gutkind JS. Class IV semaphorins promote angiogenesis by stimulating Rho-initiated pathways through plexin-B. *Cancer Res*. 2004; 64:5212–5224. [PubMed: 15289326]
- [26]. Conrotto P, Valdembri D, Corso S, Serini G, Tamagnone L, Comoglio PM, Bussolino F, Giordano S. Sema4D induces angiogenesis through Met recruitment by Plexin B1. *Blood*. 2005; 105:4321–4329. [PubMed: 15632204]
- [27]. Banu N, Teichman J, Dunlap-Brown M, Villegas G, Tufro A. Semaphorin 3C regulates endothelial cell function by increasing integrin activity. *FASEB journal : official publication of the Federation of American Societies for Experimental Biology*. 2006; 20:2150–2152. [PubMed: 16940438]
- [28]. Soker S, Miao HQ, Nomi M, Takashima S, Klagsbrun M. VEGF165 mediates formation of complexes containing VEGFR-2 and neuropilin-1 that enhance VEGF165-receptor binding. *Journal of cellular biochemistry*. 2002; 85:357–368. [PubMed: 11948691]
- [29]. Kawamura H, Li X, Goishi K, van Meeteren LA, Jakobsson L, Cebe-Suarez S, Shimizu A, Edholm D, Ballmer-Hofer K, Kjellen L, Klagsbrun M, Claesson-Welsh L. Neuropilin-1 in regulation of VEGF-induced activation of p38MAPK and endothelial cell organization. *Blood*. 2008; 112:3638–3649. [PubMed: 18664627]
- [30]. Prahst C, Heroult M, Lanahan AA, Uziel N, Kessler O, Shraga-Heled N, Simons M, Neufeld G, Augustin HG. Neuropilin-1-VEGFR-2 complexing requires the PDZ-binding domain of neuropilin-1. *The Journal of biological chemistry*. 2008; 283:25110–25114. [PubMed: 18628209]
- [31]. Herzog B, Pellet-Many C, Britton G, Hartzoulakis B, Zachary IC. VEGF binding to NRP1 is essential for VEGF stimulation of endothelial cell migration, complex formation between NRP1

- and VEGFR2, and signaling via FAK Tyr407 phosphorylation. *Molecular biology of the cell*. 2011; 22:2766–2776. [PubMed: 21653826]
- [32]. Pan Q, Chantry Y, Liang WC, Stawicki S, Mak J, Rathore N, Tong RK, Kowalski J, Yee SF, Pacheco G, Ross S, Cheng Z, Le Couter J, Plowman G, Peale F, Koch AW, Wu Y, Bagri A, Tessier-Lavigne M, Watts RJ. Blocking neuropilin-1 function has an additive effect with anti-VEGF to inhibit tumor growth. *Cancer cell*. 2007; 11:53–67. [PubMed: 17222790]
- [33]. Whitaker GB, Limberg BJ, Rosenbaum JS. Vascular endothelial growth factor receptor-2 and neuropilin-1 form a receptor complex that is responsible for the differential signaling potency of VEGF(165) and VEGF(121). *The Journal of biological chemistry*. 2001; 276:25520–25531. [PubMed: 11333271]
- [34]. Shraga-Heled N, Kessler O, Prahst C, Kroll J, Augustin H, Neufeld G. Neuropilin-1 and neuropilin-2 enhance VEGF121 stimulated signal transduction by the VEGFR-2 receptor. *FASEB journal : official publication of the Federation of American Societies for Experimental Biology*. 2007; 21:915–926. [PubMed: 17185751]
- [35]. Wang L, Zeng H, Wang P, Soker S, Mukhopadhyay D. Neuropilin-1-mediated vascular permeability factor/vascular endothelial growth factor-dependent endothelial cell migration. *The Journal of biological chemistry*. 2003; 278:48848–48860. [PubMed: 14514674]
- [36]. Cai H, Reed RR. Cloning and characterization of neuropilin-1-interacting protein: a PSD-95/Dlg/ZO-1 domain-containing protein that interacts with the cytoplasmic domain of neuropilin-1. *The Journal of neuroscience : the official journal of the Society for Neuroscience*. 1999; 19:6519–6527. [PubMed: 10414980]
- [37]. Chittenden TW, Claes F, Lanahan AA, Autiero M, Palac RT, Tkachenko EV, Elfenbein A, Ruiz de Almodovar C, Dedkov E, Tomanek R, Li W, Westmore M, Singh JP, Horowitz A, Mulligan-Kehoe MJ, Moodie KL, Zhuang ZW, Carmeliet P, Simons M. Selective regulation of arterial branching morphogenesis by synectin. *Developmental cell*. 2006; 10:783–795. [PubMed: 16740480]
- [38]. Evans IM, Yamaji M, Britton G, Pellet-Many C, Lockie C, Zachary IC, Frankel P. Neuropilin-1 signaling through p130Cas tyrosine phosphorylation is essential for growth factor-dependent migration of glioma and endothelial cells. *Molecular and cellular biology*. 2011; 31:1174–1185. [PubMed: 21245381]
- [39]. Fantin A, Schwarz Q, Davidson K, Normando EM, Denti L, Ruhrberg C. The cytoplasmic domain of neuropilin 1 is dispensable for angiogenesis, but promotes the spatial separation of retinal arteries and veins. *Development*. 2011; 138:4185–4191. [PubMed: 21852397]
- [40]. Gerhardt H, Ruhrberg C, Abramsson A, Fujisawa H, Shima D, Betsholtz C. Neuropilin-1 is required for endothelial tip cell guidance in the developing central nervous system. *Developmental dynamics : an official publication of the American Association of Anatomists*. 2004; 231:503–509. [PubMed: 15376331]
- [41]. Kitsukawa T, Shimizu M, Sanbo M, Hirata T, Taniguchi M, Bekku Y, Yagi T, Fujisawa H. Neuropilin- semaphorin III/D-mediated chemorepulsive signals play a crucial role in peripheral nerve projection in mice. *Neuron*. 1997; 19:995–1005. [PubMed: 9390514]
- [42]. Ballmer-Hofer K, Andersson AE, Ratcliffe LE, Berger P. Neuropilin-1 promotes VEGFR-2 trafficking through Rab11 vesicles thereby specifying signal output. *Blood*. 2011; 118:816–826. [PubMed: 21586748]
- [43]. Oh WJ, Gu C. The role and mechanism-of-action of Sema3E and Plexin-D1 in vascular and neural development. *Seminars in cell & developmental biology*. 2012
- [44]. Roche J, Boldog F, Robinson M, Robinson L, Varella-Garcia M, Swanton M, Waggoner B, Fishel R, Franklin W, Gemmill R, Drabkin H. Distinct 3p21.3 deletions in lung cancer and identification of a new human semaphorin. *Oncogene*. 1996; 12:1289–1297. [PubMed: 8649831]
- [45]. Xiang RH, Hensel CH, Garcia DK, Carlson HC, Kok K, Daly MC, Kerbacher K, van den Berg A, Veldhuis P, Buys CH, Naylor SL. Isolation of the human semaphorin III/F gene (SEMA3F) at chromosome 3p21, a region deleted in lung cancer. *Genomics*. 1996; 32:39–48. [PubMed: 8786119]
- [46]. Bielenberg DR, Hida Y, Shimizu A, Kaipainen A, Kreuter M, Kim CC, Klagsbrun M. Semaphorin 3F, a chemorepulsant for endothelial cells, induces a poorly vascularized,

- encapsulated, nonmetastatic tumor phenotype. *J Clin Invest.* 2004; 114:1260–1271. [PubMed: 15520858]
- [47]. Clarhaut J, Gemmill RM, Potiron VA, Ait-Si-Ali S, Imbert J, Drabkin HA, Roche J. ZEB-1, a repressor of the semaphorin 3F tumor suppressor gene in lung cancer cells. *Neoplasia.* 2009; 11:157–166. [PubMed: 19177200]
- [48]. Coma S, Amin DN, Shimizu A, Lasorella A, Iavarone A, Klagsbrun M. Id2 promotes tumor cell migration and invasion through transcriptional repression of semaphorin 3F. *Cancer research.* 2010; 70:3823–3832. [PubMed: 20388805]
- [49]. Bachelder RE, Lipscomb EA, Lin X, Wendt MA, Chadborn NH, Eickholt BJ, Mercurio AM. Competing autocrine pathways involving alternative neuropilin-1 ligands regulate chemotaxis of carcinoma cells. *Cancer research.* 2003; 63:5230–5233. [PubMed: 14500350]
- [50]. Pan H, Bachelder RE. Autocrine Semaphorin3A stimulates eukaryotic initiation factor 4E-dependent RhoA translation in breast tumor cells. *Exp Cell Res.* 2010; 316:2825–2832. [PubMed: 20655307]
- [51]. Herman JG, Meadows GG. Increased class 3 semaphorin expression modulates the invasive and adhesive properties of prostate cancer cells. *Int J Oncol.* 2007; 30:1231–1238. [PubMed: 17390026]
- [52]. Chakraborty G, Kumar S, Mishra R, Patil TV, Kundu GC. Semaphorin 3A suppresses tumor growth and metastasis in mice melanoma model. *PLoS One.* 2012; 7:e33633. [PubMed: 22448259]
- [53]. Tomizawa Y, Sekido Y, Kondo M, Gao B, Yokota J, Roche J, Drabkin H, Lerman MI, Gazdar AF, Minna JD. Inhibition of lung cancer cell growth and induction of apoptosis after reexpression of 3p21.3 candidate tumor suppressor gene SEMA3B. *Proc Natl Acad Sci U S A.* 2001; 98:13954–13959. [PubMed: 11717452]
- [54]. Nair PN, McArdle L, Cornell J, Cohn SL, Stallings RL. High-resolution analysis of 3p deletion in neuroblastoma and differential methylation of the SEMA3B tumor suppressor gene. *Cancer Genet Cytogenet.* 2007; 174:100–110. [PubMed: 17452250]
- [55]. Giordano S, Corso S, Conrotto P, Artigiani S, Gilestro G, Barberis D, Tamagnone L, Comoglio PM. The semaphorin 4D receptor controls invasive growth by coupling with Met. *Nat Cell Biol.* 2002; 4:720–724. [PubMed: 12198496]
- [56]. Conrotto P, Corso S, Gamberini S, Comoglio PM, Giordano S. Interplay between scatter factor receptors and B plexins controls invasive growth. *Oncogene.* 2004; 23:5131–5137. [PubMed: 15184888]
- [57]. Basile JR, Castilho RM, Williams VP, Gutkind JS. Semaphorin 4D provides a link between axon guidance processes and tumor-induced angiogenesis. *Proc Natl Acad Sci U S A.* 2006; 103:9017–9022. [PubMed: 16754882]
- [58]. Catalano A, Lazzarini R, Di Nuzzo S, Orciari S, Procopio A. The plexin-A1 receptor activates vascular endothelial growth factor-receptor 2 and nuclear factor-kappaB to mediate survival and anchorage-independent growth of malignant mesothelioma cells. *Cancer research.* 2009; 69:1485–1493. [PubMed: 19176370]
- [59]. Serini G, Maione F, Giraudo E, Bussolino F. Semaphorins and tumor angiogenesis. *Angiogenesis.* 2009; 12:187–193. [PubMed: 19266292]
- [60]. Neufeld G, Sabag AD, Rabinovicz N, Kessler O. Semaphorins in angiogenesis and tumor progression. *Cold Spring Harb Perspect Med.* 2012; 2:a006718. [PubMed: 22315716]
- [61]. Serini G, Bussolino F, Maione F, Giraudo E. Class 3 semaphorins: physiological vascular normalizing agents for anti-cancer therapy. *J Intern Med.* 2012
- [62]. Tamagnone L. Emerging role of semaphorins as major regulatory signals and potential therapeutic targets in cancer. *Cancer Cell.* 2012; 22:145–152. [PubMed: 22897846]
- [63]. Serini G, Valdembri D, Zanivan S, Morterra G, Burkhardt C, Caccavari F, Zammataro L, Primo L, Tamagnone L, Logan M, Tessier-Lavigne M, Taniguchi M, Puschel AW, Bussolino F. Class 3 semaphorins control vascular morphogenesis by inhibiting integrin function. *Nature.* 2003; 424:391–397. [PubMed: 12879061]
- [64]. Maione F, Molla F, Meda C, Latini R, Zentilin L, Giacca M, Seano G, Serini G, Bussolino F, Giraudo E. Semaphorin 3A is an endogenous angiogenesis inhibitor that blocks tumor growth

- and normalizes tumor vasculature in transgenic mouse models. *J Clin Invest*. 2009; 119:3356–3372. [PubMed: 19809158]
- [65]. Casazza A, Fu X, Johansson I, Capparuccia L, Andersson F, Giustacchini A, Squadrito ML, Venneri MA, Mazzone M, Larsson E, De Palma M, Naldini L, Tamagnone L, Rolny C. Systemic and Targeted Delivery of Semaphorin 3A Inhibits Tumor Angiogenesis and Progression in Mouse Tumor Models. *Arterioscler Thromb Vasc Biol*. 2011; 31:741–749. [PubMed: 21205984]
- [66]. Carmeliet P, Jain RK. Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases. *Nat Rev Drug Discov*. 2011; 10:417–427. [PubMed: 21629292]
- [67]. Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. *Science*. 2005; 307:58–62. [PubMed: 15637262]
- [68]. Goel S, Duda DG, Xu L, Munn LL, Boucher Y, Fukumura D, Jain RK. Normalization of the vasculature for treatment of cancer and other diseases. *Physiol Rev*. 2011; 91:1071–1121. [PubMed: 21742796]
- [69]. Sorensen AG, Emblem KE, Polaskova P, Jennings D, Kim H, Ancukiewicz M, Wang M, Wen PY, Ivy P, Batchelor TT, Jain RK. Increased survival of glioblastoma patients who respond to antiangiogenic therapy with elevated blood perfusion. *Cancer research*. 2012; 72:402–407. [PubMed: 22127927]
- [70]. Maione F, Capano S, Regano D, Zentilin L, Giacca M, Casanovas O, Bussolino F, Serini G, Giraudo E. Semaphorin 3A overcomes cancer hypoxia and metastatic dissemination induced by antiangiogenic treatment in mice. *J Clin Invest*. 2012; 122:1832–1848.
- [71]. Rapisarda A, Melillo G. Overcoming disappointing results with antiangiogenic therapy by targeting hypoxia. *Nat Rev Clin Oncol*. 2012; 9:378–390. [PubMed: 22525710]
- [72]. Sennino B, Ishiguro-Oonuma T, Wei Y, Naylor RM, Williamson CW, Bhagwandin V, Tabruyn SP, You WK, Chapman HA, Christensen JG, Aftab DT, McDonald DM. Suppression of tumor invasion and metastasis by concurrent inhibition of c-Met and VEGF signaling in pancreatic neuroendocrine tumors. *Cancer Discov*. 2012; 2:270–287. [PubMed: 22585997]
- [73]. Kessler O, Shrager-Heled N, Lange T, Gutmann-Raviv N, Sabo E, Baruch L, Machluf M, Neufeld G. Semaphorin-3F is an inhibitor of tumor angiogenesis. *Cancer research*. 2004; 64:1008–1015. [PubMed: 14871832]
- [74]. Wong HK, Lahdenranta J, Kamoun WS, Chan AW, McClatchey AI, Plotkin SR, Jain RK, di Tomaso E. Anti-vascular endothelial growth factor therapies as a novel therapeutic approach to treating neurofibromatosis-related tumors. *Cancer research*. 2010; 70:3483–3493. [PubMed: 20406973]
- [75]. Wong HK, Shimizu A, Kirkpatrick ND, Garkavtsev I, Chan AW, di Tomaso E, Klagsbrun M, Jain RK. Merlin/NF2 Regulates Angiogenesis in Schwannomas through a Rac1/Semaphorin 3F-Dependent Mechanism. *Neoplasia*. 2012; 14:84–94. [PubMed: 22431917]
- [76]. Sakurai A, Gavard J, Annas-Linhares Y, Basile JR, Amornphimoltham P, Palmby TR, Yagi H, Zhang F, Randazzo PA, Li X, Weigert R, Gutkind JS. Semaphorin 3E initiates antiangiogenic signaling through plexin D1 by regulating Arf6 and R-Ras. *Mol Cell Biol*. 2010; 30:3086–3098. [PubMed: 20385769]
- [77]. Christensen C, Ambartsumian N, Gilestro G, Thomsen B, Comoglio P, Tamagnone L, Guldborg P, Lukanidin E. Proteolytic processing converts the repelling signal Sema3E into an inducer of invasive growth and lung metastasis. *Cancer Res*. 2005; 65:6167–6177. [PubMed: 16024618]
- [78]. Casazza A, Finisguerra V, Capparuccia L, Camperi A, Swiercz JM, Rizzolio S, Rolny C, Christensen C, Bertotti A, Sarotto I, Risio M, Trusolino L, Weitz J, Schneider M, Mazzone M, Comoglio PM, Tamagnone L. Sema3E-Plexin D1 signaling drives human cancer cell invasiveness and metastatic spreading in mice. *J Clin Invest*. 2010; 120:2684–2698. [PubMed: 20664171]
- [79]. Casazza A, Kigel B, Maione F, Capparuccia L, Kessler O, Giraudo E, Mazzone M, Neufeld G, Tamagnone L. Tumour growth inhibition and anti-metastatic activity of a mutated furin-resistant Semaphorin 3E isoform. *EMBO Mol Med*. 2012; 4:234–250. [PubMed: 22247010]
- [80]. Varshavsky A, Kessler O, Abramovitch S, Kigel B, Zaffryar S, Akiri G, Neufeld G. Semaphorin-3B is an angiogenesis inhibitor that is inactivated by furin-like pro-protein convertases. *Cancer research*. 2008; 68:6922–6931. [PubMed: 18757406]

- [81]. Sabag AD, Bode J, Fink D, Kigel B, Kugler W, Neufeld G. Semaphorin-3D and semaphorin-3E inhibit the development of tumors from glioblastoma cells implanted in the cortex of the brain. *LoS One*. 2012; 7:e42912.
- [82]. Sadanandam A, Rosenbaugh EG, Singh S, Varney M, Singh RK. Semaphorin 5A promotes angiogenesis by increasing endothelial cell proliferation, migration, and decreasing apoptosis. *Microvasc Res*. 2010; 79:1–9. [PubMed: 19850054]
- [83]. Hanahan D, Coussens LM. Accessories to the crime: functions of cells recruited to the tumor microenvironment. *Cancer Cell*. 2012; 21:309–322. [PubMed: 22439926]
- [84]. Pietras K, Ostman A. Hallmarks of cancer: interactions with the tumor stroma. *Exp Cell Res*. 2010; 316:1324–1331. [PubMed: 20211171]
- [85]. Squadrito ML, De Palma M. Macrophage regulation of tumor angiogenesis: implications for cancer therapy. *Mol Aspects Med*. 2011; 32:123–145. [PubMed: 21565215]
- [86]. Mitchell DC, Bryan BA. Anti-angiogenic therapy: adapting strategies to overcome resistant tumors. *J Cell Biochem*. 2010; 111:543–553. [PubMed: 20626031]
- [87]. Qian BZ, Pollard JW. Macrophage diversity enhances tumor progression and metastasis. *Cell*. 2010; 141:39–51. [PubMed: 20371344]
- [88]. Takamatsu H, Kumanogoh A. Diverse roles for semaphorin-plexin signaling in the immune system. *Trends Immunol*. 2012; 33:127–135. [PubMed: 22325954]
- [89]. Rolny C, Capparuccia L, Casazza A, Mazzone M, Vallario A, Cignetti A, Medico E, Carmeliet P, Comoglio PM, Tamagnone L. The tumor suppressor semaphorin 3B triggers a prometastatic program mediated by interleukin 8 and the tumor microenvironment. *J Exp Med*. 2008; 205:1155–1171. [PubMed: 18458115]
- [90]. Toyofuku T, Yabuki M, Kamei J, Kamei M, Makino N, Kumanogoh A, Hori M. Semaphorin-4A, an activator for T-cell-mediated immunity, suppresses angiogenesis via Plexin-D1. *EMBO J*. 2007; 26:1373–1384. [PubMed: 17318185]
- [91]. Meda C, Molla F, De Pizzol M, Regano D, Maione F, Capano S, Locati M, Mantovani A, Latini R, Bussolino F, Giraudo E. Semaphorin 4A exerts a proangiogenic effect by enhancing vascular endothelial growth factor-A expression in macrophages. *J Immunol*. 2012; 188:4081–4092. [PubMed: 22442441]
- [92]. Ghanem RC, Han KY, Rojas J, Ozturk O, Kim DJ, Jain S, Chang JH, Azar DT. Semaphorin 7A promotes angiogenesis in an experimental corneal neovascularization model. *Curr Eye Res*. 2011; 36:989–996. [PubMed: 21999225]
- [93]. Suzuki K, Okuno T, Yamamoto M, Pasterkamp RJ, Takegahara N, Takamatsu H, Kitao T, Takagi J, Rennert PD, Kolodkin AL, Kumanogoh A, Kikutani H. Semaphorin 7A initiates T-cell-mediated inflammatory responses through alpha1beta1 integrin. *Nature*. 2007; 446:680–684. [PubMed: 17377534]
- [94]. Sierra JR, Corso S, Caione L, Cepero V, Conrotto P, Cignetti A, Piacibello W, Kumanogoh A, Kikutani H, Comoglio PM, Tamagnone L, Giordano S. Tumor angiogenesis and progression are enhanced by Sema4D produced by tumor-associated macrophages. *J Exp Med*. 2008; 205:1673–1685. [PubMed: 18559453]
- [95]. Pucci F, Venneri MA, Bizziato D, Nonis A, Moi D, Sica A, Di Serio C, Naldini L, De Palma M. A distinguishing gene signature shared by tumor-infiltrating Tie2-expressing monocytes, blood "resident" monocytes, and embryonic macrophages suggests common functions and developmental relationships. *Blood*. 2009; 114:901–914. [PubMed: 19383967]
- [96]. Ji JD, Park-Min KH, Ivashkiv LB. Expression and function of semaphorin 3A and its receptors in human monocyte-derived macrophages. *Hum Immunol*. 2009; 70:211–217. [PubMed: 19480842]
- [97]. Zacchigna S, Pattarini L, Zentilin L, Moimas S, Carrer A, Sinigaglia M, Arsic N, Tafuro S, Sinagra G, Giacca M. Bone marrow cells recruited through the neuropilin-1 receptor promote arterial formation at the sites of adult neoangiogenesis in mice. *J Clin Invest*. 2008; 118:2062–2075. [PubMed: 18483621]
- [98]. Carrer A, Moimas S, Zacchigna S, Pattarini L, Zentilin L, Ruozzi G, Mano M, Sinigaglia M, Maione F, Serini G, Giraudo E, Bussolino F, Giacca M. Neuropilin-1 Identifies a Subset of Bone Marrow Gr1- Monocytes That Can Induce Tumor Vessel Normalization and Inhibit Tumor Growth. *Cancer research*, (2012). 2012; 72:6371–81.

- [99]. Cirri P, Chiarugi P. Cancer-associated-fibroblasts and tumour cells: a diabolic liaison driving cancer progression. *Cancer Metastasis Rev.* 2012; 31:195–208. [PubMed: 22101652]
- [100]. Yaqoob U, Cao S, Shergill U, Jagavelu K, Geng Z, Yin M, de Assuncao TM, Cao Y, Szabolcs A, Thorgeirsson S, Schwartz M, Yang JD, Ehman R, Roberts L, Mukhopadhyay D, Shah VH. Neuropilin-1 stimulates tumor growth by increasing fibronectin fibril assembly in the tumor microenvironment. *Cancer research*, (2012). 2012; 72:4047–59.
- [101]. Cao Y, Szabolcs A, Dutta SK, Yaqoob U, Jagavelu K, Wang L, Leof EB, Urrutia RA, Shah VH, Mukhopadhyay D. Neuropilin-1 mediates divergent R-Smad signaling and the myofibroblast phenotype. *J Biol Chem.* 2010; 285:31840–31848. [PubMed: 20675371]
- [102]. Erez N, Truitt M, Olson P, Arron ST, Hanahan D. Cancer-Associated Fibroblasts Are Activated in Incipient Neoplasia to Orchestrate Tumor-Promoting Inflammation in an NF-kappaB-Dependent Manner. *Cancer Cell.* 2010; 17:135–147. [PubMed: 20138012]
- [103]. Rizzolio S, Rabinowicz N, Rainero E, Lanzetti L, Serini G, Norman J, Neufeld G, Tamagnone L. Neuropilin-1-dependent regulation of EGF-receptor signaling. *Cancer research.* 2012; 72:5801–5811. [PubMed: 22986738]

Fig.1. Schematic representation of specific interactions between semaphorins and their receptors (neuropilins and plexins)

Semaphorins can be categorized into eight distinct classes. Class 1 and 2 semaphorins are found in invertebrates, whereas classes 3-7 are expressed in vertebrates. The last class of semaphorins includes those encoded by viruses. Class 2 and 3 semaphorins as well as viral semaphorins are secreted. Class 4, 5 and 6 semaphorins are transmembrane proteins and those in class 7 are membrane-anchored via glycosylphosphatidylinositol (GPI). All semaphorins consist of a large Sema domain and PSI domain. Additional domains that are present in semaphorins include immunoglobulin (Ig)-like domains and thrombospondin repeats. Semaphorins signal through plexin receptors. Plexin A and Plexin B are found in invertebrates. In contrast, vertebrates have four A-type plexins, three B-type plexins, one C-type plexins and one D-type plexin. Plexins contain a Sema domain as well as PSI and IPT domains. Moreover, the cytoplasmic domain of plexins contains two GAP domains, a GTP-ase binding domain and a PDZ domain (characteristic only for B-type plexins). In invertebrates, Sema1s and Sema2s signal through PlexinA and PlexinB, respectively. In vertebrates, Sema3s, Sema5s and Sema6s signal through PlexinAs, with Sema3s also requiring neuropilins (Nrp1 or Nrp2) to facilitate signaling. Neuropilins are transmembrane receptors that are comprised of two complement-like (CUB) domains, two FV/FVIII coagulation factor-like domains and a meprin-like MAM domain and short cytoplasmic tail. Sema3E can also bind directly to PlexinD1 without neuropilins. Class 4 semaphorins interact with PlexinBs while Sema4A can bind to PlexinD1. Sema3A has been suggested to bind to Nrp1/PlexinD1 complex. SEMA7A and viral semaphorins interact with PlexinC1. In addition, Semas and their receptors can also modulate multiple signals in tumors by interacting with receptor tyrosine kinases and integrins (not shown here due to the limitation of space). Semas, Nrps and Plexins are aberrantly expressed in human cancer and tumor microenvironment cells. Different Semas and their receptors, can be differently over-expressed or down-modulated or mutated, depending on the tumor types. Different

Semaphorins and their respective receptor(s) regulated different types and aspect of developmental angiogenesis and tumor progression.